Law360, New York (October 31, 2007, 12:00 AM ET) -- Alza Corp. is fighting a bid by indirect purchasers in the multidistrict litigation over bladder control drug Ditropan XL to review the company’s privileged communications on the theory that Alza committed fraud by intentionally failing to disclose a prior art patent.
In court documents filed Wednesday in the U.S. District Court for the Northern District of California, Alza said that the plaintiffs have not backed up their claim that inventors and patent attorneys at Alza actually knew about the so-called Morella patent and its materiality at...
Alza Fights Bid For Attorney-Client Privileged Docs
To view the full article, take a free trial now.
